Evotec AG's near-term partnering options narrowed on news that its smoking cessation drug EVT 302 failed to demonstrate efficacy in a Phase II proof-of-concept trial involving 414 smokers. (BioWorld International) Read More
No Abstract BioWorld International CorrespondentPARIS - SpePharm Holding BV plans to file a claim against BioAlliance Pharma SA for financial damages and losses of at least €35 million (US$45.3 million). Read More
